Showing results (191-200 of 204) with videos related to
Sort By:
Pageof 21
JCI Insight|February 23, 2021
Crosstalk between nonclassical monocytes and alveolar macrophages mediates transplant ischemia-reperfusion injury through classical monocyte recruitmentChitaru Kurihara, Emilia Lecuona, Qiang Wu, et al.Frontiers in Immunology|March 12, 2021
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell TreatmentZhiling Yan, Huanxin Zhang, Jiang Cao, et al.The Journal of Clinical Investigation|July 22, 2020
Residual endotoxin induces primary graft dysfunction through ischemia/reperfusion-primed alveolar macrophagesMahzad Akbarpour, Emilia Lecuona, Stephen F Chiu, et al.Frontiers in Immunology|September 5, 2022
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphomaHuanxin Zhang, Zhiling Yan, Ying Wang, et al.The Journal of Clinical Investigation|November 15, 2024
Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasisXianpeng Liu, Ziyou Ren, Can Tan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ TrialJieyun Xia, Hujun Li, Zhiling Yan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple MyelomaYing Wang, Jiang Cao, Weiying Gu, et al.Cancer Medicine|July 2, 2020
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphomaWei Sang, Ming Shi, Jingjing Yang, et al.Scientific Reports|January 26, 2017
Genome-wide association study identifies four SNPs associated with response to platinum-based neoadjuvant chemotherapy for cervical cancerXiong Li, Kecheng Huang, Qinghua Zhang, et al.The Lancet. Haematology|April 14, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trialJieyun Xia, Qian Sun, Dian Zhou, et al.Pageof 21